Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients

Grant

Date/time Interval

  • September 18, 2018 - August 31, 2021
  • Total Award Amount

  • 1128634.00
  • Direct Costs

  • 1032099.00
  • Sponsor Award Id

  • R01CA222903
  • Contributor

  • Aban, Inmaculada   Investigator  
  • Cutter, Gary   Investigator  
  • Gillespie, George   Investigator  
  • Leavenworth Ph.D., Jianmei   Investigator  
  • Markert M.D., M.P.H., James   Principal Investigator  
  • Miller, C. Ryan   Investigator  
  • Nabors M.D., Louis   Investigator